Skip to content

Multicenter Trial of Sublingual Immunotherapy With a Solution of Grass Pollen Allergen Extract in Children

... Study to Evaluate Efficacy and Safety of Perennial Sublingual SIT With a Solution of Grass Pollen Allergen ... in Children With Clinically Relevant Grass Pollen Sensitivity in Comparison to a ... Standard Treatment With Add on Placebo

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00841256
Enrollment
207
Registered
2009-02-11
Start date
2008-02-29
Completion date
2015-08-31
Last updated
2015-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergic Rhinoconjunctivitis

Keywords

specific immunotherapy, SIT, SLIT, sublingual

Brief summary

Evaluation of safety and efficacy of sublingual immunotherapy with grass pollen allergens formulated as solution in comparison to a symptomatic standard treatment with add on placebo in grass pollen allergic children suffering from allergic rhinitis/rhinoconjunctivitis with or without bronchial asthma.

Detailed description

Although highly effective, subcutaneous administration of allergens may cause inconvenience in some patients. Alternative routes, e.g. nasal and oral, have therefore been investigated to find an immunotherapy regimen largely accepted by all groups of patients, including children. Sublingual specific immunotherapy (SLIT) may represent a more acceptable route of immunotherapy. It may be an optimal therapy option especially for children because they often fear injections. In this study children are to be treated with a preparation of a grass pollen allergen extract in a water/glycerol solution with phosphate buffered saline in comparison to a symptomatic standard treatment with add on placebo, in order to investigate efficacy and safety of the study drug.

Interventions

BIOLOGICALGrass pollen allergens in a water/glycerol solution

In total up to 4 drops (dose for maintenance therapy) are administered under the tongue.

DRUGPlacebo

Placebo was given in the same way as the sublingual active treatment. Symptomatic standard treatment, i.e. antihistamines and glucocorticoids as well as alphamimetics is allowed during grass pollen season.

Sponsors

Allergopharma GmbH & Co. KG
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
4 Years to 11 Years
Healthy volunteers
No

Inclusion criteria

* 4 - \<12 years (at the time of inclusion) * Positive SPT * Positive EAST * Positive CPT

Exclusion criteria

* Serious chronic diseases * Other perennial allergies

Design outcomes

Primary

MeasureTime frameDescription
Changes of Symptom-Medication-ScoreAfter 1 year of treatmentThe change of the area under the curve of the symptom and medication score (SMS) from the baseline season to the season after 1 year of treatment.

Secondary

MeasureTime frameDescription
Evaluation of the documentation of adverse events (AEs)Entire treatment periodSafety of treatments during the entire treatment period.

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 25, 2026